KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has disclosed Total Debt for 4 consecutive years, with $15.7 million as the latest value for Q1 2020.

  • On a quarterly basis, Total Debt rose 3.55% to $15.7 million in Q1 2020 year-over-year; TTM through Mar 2020 was $15.7 million, a 3.55% increase, with the full-year FY2019 number at $15.5 million, changed N/A from a year prior.
  • Total Debt was $15.7 million for Q1 2020 at Xenon Pharmaceuticals, up from $15.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $15.7 million in Q1 2020 to a low of $6.8 million in Q4 2017.
  • A 4-year average of $13.0 million and a median of $15.1 million in 2019 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 120.17% in 2019; the steepest drop was 3.47% in 2019.
  • Xenon Pharmaceuticals' Total Debt stood at $6.8 million in 2017, then skyrocketed by 118.78% to $14.9 million in 2018, then increased by 4.39% to $15.5 million in 2019, then rose by 0.88% to $15.7 million in 2020.
  • Per Business Quant, the three most recent readings for XENE's Total Debt are $15.7 million (Q1 2020), $15.5 million (Q4 2019), and $15.4 million (Q3 2019).